Alpha-Synuclein in Action
PDF-funded scientist-clinician Kateri Spinelli, Ph.D., is using cutting-edge technology to see how a potential culprit (the protein alpha-synuclein) works in Parkinson's disease.Learn More
Your Donations Make a Difference
Your support makes the research of Dr. Hess and Dr. Earhart possible, allowing us to learn about the role of genetics and the potential of exercise in Parkinson's.
Watch Our Video & Learn More
Tuesday, March 1 (Online)
While many people with PD will experience some degree of mild cognitive change, it is estimated that at any given time, about one quarter to one third of people with PD are experiencing dementia. What should you know about dementia in PD? Find tips by joining a one-hour online seminar led by PDF and Jennifer G. Goldman, M.D., M.S., Associate Professor, Section of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, PDF Research Center at Rush University Medical Center.
Potential New Therapy for Reducing Levodopa “Off-time”
January 31, 2016
According to the results of a phase III clinical trial, a drug called opicapone may provide a new option for reducing “wearing-off” periods for people with Parkinson’s who take levodopa. The researchers found that opicapone is modestly more effective than entacapone (Comtan®, also an ingredient in Stalevo®), the drug most commonly prescribed today for this purpose. It also offers the convenience of only one dose a day. The study appears in the December 22 online edition of The Lancet Neurology.